 |
| (사진= 연합뉴스) |
[Alpha Biz=(Chicago) Reporter Paul Lee] Celltrion and Humasis are continuing a counter-suit over whether they violated the COVID-19 diagnostic kit contract.
Celltrion announced on the 13th that Humasis has filed a lawsuit against the company for damages. Celltrion said, "We will actively respond according to legal procedures."
At the end of last year, Humasis warned of a legal action, saying Celltrion unilaterally terminated a supply contract worth about 92 billion won. Celltrion also filed a lawsuit against Humasis on the 1st to claim damages and advance payments. Humasis announced a match with Celltrion through the appointment of a new management manager on the 9th.
In June 2020, the two companies jointly developed kits through a contract to develop and supply COVID-19 diagnostic kits and began delivering them to the U.S. market through Celltrion's U.S. subsidiary, but eventually clashed due to a supply shortage.
Celltrion claims that Humasis has deteriorated Celltrion's reputation by failing to supply products on time at a time when demand for diagnostic kits in the U.S. has soared. Humasis is citing restrictions on exports from the Ministry of Food and Drug Safety at the time as the reason for the delay in delivery.
Alphabiz Reporter Paul Lee(hoondork1977@alphabiz.co.kr)
